NO20055607L - Antilosemiddel solidifiseringsprosess - Google Patents

Antilosemiddel solidifiseringsprosess

Info

Publication number
NO20055607L
NO20055607L NO20055607A NO20055607A NO20055607L NO 20055607 L NO20055607 L NO 20055607L NO 20055607 A NO20055607 A NO 20055607A NO 20055607 A NO20055607 A NO 20055607A NO 20055607 L NO20055607 L NO 20055607L
Authority
NO
Norway
Prior art keywords
antelope
solidification process
organic
inorganic compound
solvent solidification
Prior art date
Application number
NO20055607A
Other languages
English (en)
Other versions
NO20055607D0 (no
Inventor
Robert Michael Geertman
Cornelis Elisabeth Johann Lare
Wridzer Jan Willem Bakker
Marianne Frederika Reedijk
Jozef Johannes Maria Baltussen
Gerrald Bargeman
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33418418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055607(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO20055607L publication Critical patent/NO20055607L/no
Publication of NO20055607D0 publication Critical patent/NO20055607D0/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D3/00—Halides of sodium, potassium or alkali metals in general
    • C01D3/22—Preparation in the form of granules, pieces, or other shaped products
    • C01D3/24—Influencing the crystallisation process
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Glanulating (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Colloid Chemistry (AREA)

Abstract

Forehggende oppfirmelse omhandler en antiløsemiddel sohdifiseringsprosess hvori et flytende medium som omfatter minst én organisk eller uorganisk forbindelse som skal solidifiseres blfr tvunget gjermom en membran irm i ett eller flere antiløsemidler, eller hvori ett eller flere antiløsemidler blir tvunget gjermom en membran irm i et flytende medium som omfatter minst én organisk eller uorganisk forbindelse som skal solidifiseres, hvilket gir en sammensetning som omfatter faste partikler som omfatter nevnte organiske og/eller uorganiske forbindelse(r).
NO20055607A 2003-04-29 2005-11-28 Antilosemiddel solidifiseringsprosess NO20055607D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46676103P 2003-04-29 2003-04-29
PCT/EP2004/004506 WO2004096405A1 (en) 2003-04-29 2004-04-28 Antisolvent solidification process

Publications (2)

Publication Number Publication Date
NO20055607L true NO20055607L (no) 2005-11-28
NO20055607D0 NO20055607D0 (no) 2005-11-28

Family

ID=33418418

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055607A NO20055607D0 (no) 2003-04-29 2005-11-28 Antilosemiddel solidifiseringsprosess

Country Status (22)

Country Link
US (4) US20060182808A1 (no)
EP (1) EP1620193B1 (no)
JP (1) JP5207432B2 (no)
KR (1) KR20060006949A (no)
CN (1) CN100434133C (no)
AR (1) AR044140A1 (no)
AT (1) ATE406946T1 (no)
AU (1) AU2004234057A1 (no)
BR (1) BRPI0409860A (no)
CA (1) CA2523883C (no)
CL (1) CL2004000912A1 (no)
DE (1) DE602004016311D1 (no)
ES (1) ES2312996T3 (no)
IL (1) IL171613A (no)
MX (1) MXPA05011626A (no)
MY (1) MY141189A (no)
NO (1) NO20055607D0 (no)
NZ (1) NZ543772A (no)
RU (1) RU2339364C2 (no)
TW (1) TW200500095A (no)
WO (1) WO2004096405A1 (no)
ZA (1) ZA200509597B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101262846A (zh) * 2005-07-15 2008-09-10 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
AU2006272438B2 (en) * 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
US7942990B2 (en) 2006-12-18 2011-05-17 Daicel Chemical Industries, Ltd. Hybrid inflator
MX2009007834A (es) * 2007-01-22 2009-09-10 Cargill Inc Metodo para producir composiciones de rebaudiosido a purificado usando cristalizacion en solvente/ antisolvente.
GB0705159D0 (en) * 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
FI120527B (fi) * 2007-06-18 2009-11-30 Crisolteq Oy Talteenottomenetelmä
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
TWI466709B (zh) * 2011-07-20 2015-01-01 Nat Univ Chung Hsing From the original berry Wolfberry a liquid - liquid freezing method for separation of high purity theaflavins palmitate Maize
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9452930B2 (en) * 2013-11-04 2016-09-27 New Jersey Institute Of Technology System and method for continuous polymer coating of particles
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
PT108368B (pt) 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN106853295A (zh) * 2015-12-09 2017-06-16 北大方正集团有限公司 一种基于膜分散的结晶方法
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US10881123B2 (en) 2017-10-27 2021-01-05 Frito-Lay North America, Inc. Crystal morphology for sodium reduction
WO2019239550A1 (ja) * 2018-06-14 2019-12-19 日揮株式会社 晶析装置及び晶析方法
CN119679728A (zh) * 2018-12-28 2025-03-25 四川科伦药物研究院有限公司 制备黄体酮颗粒物的方法、所得黄体酮颗粒物及其注射剂
CN111234431A (zh) * 2020-03-31 2020-06-05 宁夏颐星新材料科技有限公司 一种消泡型聚乙烯醇粉末的生产工艺
GB202004824D0 (en) 2020-04-01 2020-05-13 Naturbeads Ltd Biopolymer particle preparation
GB202011836D0 (en) 2020-07-30 2020-09-16 Micropore Tech Limited Crystallisation methods
CN115777906A (zh) * 2021-09-10 2023-03-14 吉林大学 氯化钠纳微米粒子及其制备方法和应用
EP4637720A1 (en) 2022-12-22 2025-10-29 Nanomi B.V. Process for preparing stable nanoparticle and composition thereof
CN117942426B (zh) * 2024-03-22 2024-05-31 四川大学 一种具有取向孔道结构的多级多孔材料及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716453B1 (fr) * 1994-02-22 1996-03-29 Rhone Poulenc Agrochimie Procédé de sulfinylation de composés hétérocycliques.
US4089843A (en) * 1976-09-20 1978-05-16 The Upjohn Company Precipitating polymers in powder form
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
JPH0672528B2 (ja) * 1985-07-16 1994-09-14 三信工業株式会社 船舶のエンジン
RU2026670C1 (ru) * 1988-10-05 1995-01-20 Дзе Апджон Компани Способ получения тонкодисперсного твердого фармацевтического вещества
US5269926A (en) * 1991-09-09 1993-12-14 Wisconsin Alumni Research Foundation Supported microporous ceramic membranes
FR2658498B1 (fr) * 1990-02-19 1992-05-15 Atochem Particules de chlorure de magnesium a structure tronc conique, composante catalytique supportee sur ces particules, polyolefines obtenues a partir de cette composante catalytique, procedes de fabrication de ces produits.
JP2555475B2 (ja) * 1990-10-16 1996-11-20 工業技術院長 無機質微小球体の製造方法
JP2816597B2 (ja) * 1990-11-28 1998-10-27 富士写真フイルム株式会社 溶液の均一混合装置および弾性体多孔膜
IE71202B1 (en) * 1990-12-17 1997-02-12 Akzo Nv Progestagen-only contraceptive
WO1993000156A1 (fr) * 1991-06-29 1993-01-07 Miyazaki-Ken Emulsions monodispersees simples et doubles et procede de production
SG43179A1 (en) * 1991-12-18 1997-10-17 Warner Lambert Co A process for the prepatation of a solid dispersion
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
NZ276277A (en) * 1993-11-08 1998-04-27 Gillette Co Antiperspirant compound, in aerogel form, being an aluminium salt, a zirconium salt or an aluminium-zirconium salt
JP3492787B2 (ja) * 1994-04-15 2004-02-03 信越化学工業株式会社 固形製剤のコーティング用水性エマルジョンの濃縮方法
US6387399B1 (en) * 1994-12-02 2002-05-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulated bioactive agents and method of making
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5876480A (en) * 1996-02-20 1999-03-02 The United States Of America As Represented By The Secretary Of The Navy Synthesis of unagglomerated metal nano-particles at membrane interfaces
GB9610955D0 (en) * 1996-05-24 1996-07-31 Hercules Inc Sizing composition
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable
US5879715A (en) * 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
ES2272066T3 (es) * 1998-04-09 2007-04-16 F. Hoffmann-La Roche Ag Proceso para la manufactura de particulas con tamaño de (sub)micras por disolucion de gas comprimido y surfactantes.
SE9801287D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
US6113795A (en) * 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IN191236B (no) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6780507B2 (en) * 2000-02-09 2004-08-24 Analytical Research Systems, Inc. Hydrocapsules and method of preparation thereof
US6623761B2 (en) * 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
WO2003032951A1 (en) * 2001-08-29 2003-04-24 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation
CA2462338C (en) * 2001-10-10 2011-04-19 Boehringer Ingelheim Pharmaceuticals, Inc. Powder processing with pressurized gaseous fluids
US6890592B2 (en) * 2002-03-13 2005-05-10 Appleton Papers Inc. Uniform microcapsules
US6966990B2 (en) * 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing

Also Published As

Publication number Publication date
ZA200509597B (en) 2006-12-27
CN1780670A (zh) 2006-05-31
TW200500095A (en) 2005-01-01
CL2004000912A1 (es) 2005-02-04
IL171613A (en) 2010-02-17
US20130131029A1 (en) 2013-05-23
US20120232296A1 (en) 2012-09-13
KR20060006949A (ko) 2006-01-20
RU2005136983A (ru) 2006-03-20
CN100434133C (zh) 2008-11-19
EP1620193A1 (en) 2006-02-01
CA2523883C (en) 2012-01-03
ATE406946T1 (de) 2008-09-15
US20110268806A1 (en) 2011-11-03
CA2523883A1 (en) 2004-11-11
AR044140A1 (es) 2005-08-24
AU2004234057A1 (en) 2004-11-11
MXPA05011626A (es) 2006-01-23
WO2004096405A1 (en) 2004-11-11
NZ543772A (en) 2009-05-31
EP1620193B1 (en) 2008-09-03
MY141189A (en) 2010-03-31
JP5207432B2 (ja) 2013-06-12
JP2006524565A (ja) 2006-11-02
NO20055607D0 (no) 2005-11-28
RU2339364C2 (ru) 2008-11-27
ES2312996T3 (es) 2009-03-01
HK1088268A1 (en) 2006-11-03
BRPI0409860A (pt) 2006-05-16
DE602004016311D1 (de) 2008-10-16
US20060182808A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
MY141189A (en) Antisolvent solidification process
FI20031642A0 (fi) Oksapuu-uutteiden uusi käyttö
DE60232468D1 (de) Ente und damit zusammenhängende verfahren
ATE414992T1 (de) Elektroosmotische pumpen und mikrokanäle
CY1111817T1 (el) Απομακρυνση του διαλυτη με μια διαδικασια προσθιας οσμωσης
EA201070610A1 (ru) Способы получения и применения вспомогательного газа
NO20042321L (no) Partikkelfjerningssystem
BRPI0413289A (pt) método para produzir um material poroso, e, material poroso
DK1652909T4 (da) Korrosionsbeskyttelsesmiddel til funktionelle væsker, vandblandbart koncentrat og anvendelse heraf
ATE556788T1 (de) Herstellung pharmazeutischer wirkstoffpartikel unter verwendung fokussierter akustischer energie
BR0306737A (pt) Uso de um agente deionizante lìquido, processo para deionização de um meio de resfriamento de uma célula de combustìvel, e, aparelho de célula de combustìvel
ATE466910T1 (de) Verfahren zum reinigen von pigmentzusammensetzungen
AP2006003495A0 (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections.
ATE365801T1 (de) Modulierung durch il-tif/interleukin-21
DE502005005498D1 (de) Verfahren zur Herstellung fester Treibmittelpräparationen
DK1638609T3 (da) Fremgangsmåde til fremstilling af molekylekomplekser
EA201991962A1 (ru) Агент для извлечения металлов, агент для извлечения соединений металлов и способ извлечения металлов или соединений металлов
ATE534454T1 (de) Verfahren zum einbringen einer lösung in eine verdampfungs-kühlanlage
CY1115474T1 (el) Χρωματογραφικη μεθοδος
FI20085651A7 (fi) Palonsammutusjärjestelmä
BRPI0412469A (pt) sistema de comunicação, computador de filtro de mensagens peer-to-peer e processo para o processamento pra o processamento de uma mensagem peer-to-peer
RU99127483A (ru) Способ бальзамирования анатомических препаратов силоксановыми композициями
DE502007002510D1 (de) Keramische Einbettmasse zur Herstellung einer Giessform sowie damit verbundene Herstellungsverfahren
FI20050708A7 (fi) Menetelmä polystyreenin kierrättämiseksi
TW200714688A (en) Method for regenerating fluorescent material and fluorescent lamp

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application